ejpmr, 2025, 12(8), 127-139

EUROPEAN JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.ejpmr.com

SJIF Impact Factor 7.065

Review Article

ISSN (O): 2394-3211

ISSN (P): 3051-2573

AI ALGORITHMS FOR ADVANCED PHARMACEUTICAL DRUG ANALYSIS AND QUALITY CONTROL

Vanitha Devi Rajendran, Pavithra Ravikumar, Guhan Ramalingam, Maruthachalam Chinnaiah, Balakumar Palanivelu and Vinoth Jeevanesan*

Sir Issac Newton College of Pharmacy, Nagapattinam, Tamil Nadu - 611 102, India.

***Corresponding Author: Vinoth Jeevanesan**

Sir Issac Newton College of Pharmacy, Nagapattinam, Tamil Nadu - 611 102, India.

Article Received on 10/06/2025 **Article Revised on 30/06/2025** **Article Accepted on 21/07/2025**

ABSTRACT

The integration of Artificial Intelligence (AI) into pharmaceutical drug analysis and quality control (QC) is transforming conventional practices by enabling predictive, real-time and highly automated systems. While traditional analytical methods remain foundational, they face increasing challenges due to the complexity of modern datasets, evolving regulatory standards and the demand for accelerated decision-making. AI algorithms, such as deep neural networks, random forests and graph neural networks, have demonstrated significant advancements in spectral interpretation, chromatographic analysis, image-based defect detection and stability prediction. This review presents a comprehensive analysis of current and emerging AI models applied across various domains of pharmaceutical QC. Platforms including Aizon, Mestrelab Mnova AI and ChemOS utilize spectral data to rapidly identify polymorphs and impurities. Chromatographic and mass spectrometric analyses are increasingly automated and enhanced by tools such as ChromGenius AI™, Empower™ 3 and MolDiscovery. Shelf-life prediction systems, including Stability.AI and ValGenesis iRisk™, offer robust modelling capabilities, while QualiVision and DeepInspect lead in image-based inspection of solid dosage forms. Additionally, innovations from Seeq + AWS ML, AstraZeneca's DPK models and Atomwise exemplify AI's growing role in real-time monitoring and predictive quality assurance. The convergence of AI with Quality by Design (QbD), Process Analytical Technology (PAT) and Real-Time Release Testing (RTRT) is not only improving regulatory compliance but also enhancing manufacturing efficiency. As the pharmaceutical industry embraces digital transformation, AI stands as a cornerstone of next-generation analytical and quality paradigms.

KEYWORDS: Artificial Intelligence, Drug Analysis, Quality Control, Machine Learning, Spectroscopy, Predictive Modelling.

INTRODUCTION

Pharmaceutical analysis and quality control (QC) are foundational pillars of drug development and manufacturing, ensuring that pharmaceutical products meet established standards of safety, efficacy and regulatory compliance. Analytical testing spans the entire drug lifecycle, from raw material verification and in-process monitoring to final product release, employing established techniques such as chromatography, spectroscopy and dissolution profiling. QC also encompasses visual inspection, stability testing and regulatory compliance assessments in line with Good Manufacturing Practices (GMP). The accuracy and reliability of these processes are vital for safeguarding patient health and upholding market authorization standards.

However, traditional QC methods, though reliable, are increasingly challenged by the growing complexity of pharmaceutical products and the demand for higher throughput, precision and real-time responsiveness. Conventional workflows often depend on manual data interpretation, repetitive testing procedures and fragmented data ecosystems. These limitations introduce risks such as operator bias, inefficiency, delayed decision-making and limited scalability. The emergence of complex formulations, such as biologics, biosimilars and nanomedicines, requires more advanced, data-rich analytical approaches. Legacy systems frequently struggle to manage the volume and intricacy of multivariate data, particularly in contexts requiring real-time monitoring and adaptive control.[1]

In response, the pharmaceutical industry is undergoing a digital transformation, with Artificial Intelligence (AI), including its subfields such as machine learning (ML), deep learning (DL) and neural networks, emerging as a catalyst for innovation in QC. AI technologies offer capabilities such as automated data interpretation, predictive modelling, image-based defect detection and

continuous process monitoring. For instance, AI can analyse complex spectral patterns, detect subtle anomalies in high-resolution images of solid dosage forms and predict product stability under diverse storage conditions. These advancements enhance analytical precision, accelerate release timelines and reduce human error through data-driven decision-making.[2]

Regulatory bodies have begun encouraging the adoption of such advanced technologies within frameworks like Quality by Design (QbD), Process Analytical Technology (PAT) and Real-Time Release Testing (RTRT). These initiatives promote a proactive, data-centric approach to pharmaceutical quality. AI aligns seamlessly with these principles, enabling real-time insights, adaptive control systems and improved traceability. By facilitating a shift from reactive to predictive quality models, AI supports consistent product quality in increasingly complex manufacturing environments.[3,4]

This review provides a comprehensive overview of current and emerging AI algorithms and platforms utilized in pharmaceutical drug analysis and quality control. It explores applications across spectral analysis, chromatographic interpretation, mass spectrometry, image-based inspection and stability prediction. Commercial tools such as Aizon, Mestrelab Mnova AI, Empower™ and DeepInspect are discussed for their contributions to automation, accuracy and real-time analytics. Furthermore, the convergence of AI with QbD and PAT is examined, highlighting the synergistic potential for enhancing regulatory compliance, operational efficiency and product consistency. By analysing both established applications and future directions, this review underscores AI's transformative role in redefining analytical and quality paradigms within the pharmaceutical industry.

FUNDAMENTALS OF AI IN PHARMA

Artificial Intelligence (AI) is rapidly transforming innovation in the pharmaceutical industry by enabling data-driven decision-making, process automation and real-time optimization. In the context of pharmaceutical analysis and quality control (QC), AI enhances tasks such as impurity detection in spectral data, shelf-life prediction and automated visual inspections. These intelligent technologies convert conventional workflows into adaptive, high-performance systems, improving speed, accuracy and consistency while supporting regulatory priorities focused on digitalization, traceability and data integrity.[5] As AI capabilities mature, their integration is driving a more proactive, efficient and reliable approach to drug development and manufacturing.

AI refers to computer systems capable of performing tasks traditionally requiring human intelligence. In pharmaceutical applications, AI operates mainly through subfields such as machine learning (ML), deep learning (DL) and artificial neural networks (ANNs), each contributing to automation and predictive power in analytical and quality processes. ML enables systems to learn from data and improve their performance over time without explicit reprogramming. These algorithms are especially effective in interpreting complex pharmaceutical datasets, such as chromatograms, mass spectra and high-resolution images, by identifying intricate patterns and correlations.[6] Supervised learning, a common ML approach, involves training models on labelled datasets, such as spectral profiles with known impurity levels, to predict outcomes in new data. In contrast, unsupervised learning uncovers hidden structures in unlabelled data, proving valuable for exploratory analysis and anomaly detection.[7]

DL, a specialized branch of ML, employs multilayered neural networks to model large, complex datasets. It is particularly suited to pharmaceutical contexts where data complexity and volume are substantial. For example, convolutional neural networks (CNNs) are widely used for image-based tasks such as detecting surface defects in tablets and capsules, while recurrent neural networks (RNNs) are useful for analysing time-series data, such as process monitoring trends or long-term stability behaviour. ANNs serve as the core architecture behind most DL models.[8] Inspired by the structure of the human brain, they comprise interconnected layers of nodes (neurons) that process inputs and produce output predictions. Depending on their design, these networks can perform classification (e.g., identifying defective tablets), regression (e.g., predicting degradation rates) or clustering (e.g., grouping chromatographic peak profiles).[9]

In addition to neural networks, ensemble learning techniques such as random forests and gradient boosting are widely used in pharmaceutical analytics for their robustness and improved accuracy.[10] These methods combine outputs from multiple models to generate more stable and reliable predictions. Support Vector Machines (SVMs) also remain valuable, especially for binary classification tasks like determining batch conformity or dosage uniformity.[11] The widespread adoption of AI in the pharmaceutical sector is further supported by advancements in high-performance computing, cloud infrastructure and regulatory encouragement through programs like the FDA's Emerging Technology Program.[12] Moreover, AI capabilities are increasingly being embedded into commercial platforms tailored for pharmaceutical workflows, making them more scalable, interoperable and accessible across both quality control and analytical operations.

TYPES OF AI ALGORITHMS IN PHARMACEUTICAL APPLICATIONS

Supervised vs. Unsupervised Learning

Supervised and unsupervised learning are two core machine learning paradigms, each serving distinct roles in pharmaceutical analysis and quality control.

Supervised learning uses labelled datasets, where inputs are linked to known outputs. The algorithm learns this mapping during training, enabling accurate predictions on new data. In pharmaceutical QC, supervised learning is widely applied in impurity detection from chromatographic or spectral data, assay value prediction, dosage form classification based on dissolution profiles and tablet defect identification from images. Due to its transparency and validation ease, supervised learning is well-suited to regulated environments requiring traceability and interpretability.[13]

Unsupervised learning, on the other hand, works with unlabelled data to uncover hidden structures, patterns or clusters without predefined targets. It is valuable in exploratory tasks such as identifying unknown impurities, clustering formulation behaviours or analysing complex metabolic profiles. Techniques like k-means clustering and Principal Component Analysis (PCA) are commonly employed. Although less interpretable and not inherently predictive, unsupervised learning excels in early risk detection, anomaly discovery and generating hypotheses when labelled data is scarce.[14]

In pharmaceutical contexts, these approaches often complement each other. Supervised learning offers precision and regulatory alignment, while unsupervised learning provides exploratory power and pattern recognition in complex datasets. Together, they support data-driven decision-making across development, manufacturing and quality assurance.

Deep Neural Network Architectures in Pharmaceutical Analysis

Advanced deep learning architectures, particularly Deep Neural Networks (DNNs), Convolutional Neural Networks (CNNs) and Recurrent Neural Networks (RNNs), form the foundation of many modern AI applications in pharmaceutical analysis and quality control. These architectures are designed to extract complex, hierarchical patterns from high-dimensional data, making them well suited for a variety of pharmaceutical tasks, from predictive modelling to automated visual inspection.

1. Deep Neural Networks (DNNs)

DNNs consist of multiple layers of interconnected artificial neurons capable of learning complex, non-linear relationships from large datasets. In pharmaceutical contexts, DNNs have been applied to predict drug dissolution rates, forecast stability profiles and model process behaviours based on multivariate sensor data. Their ability to learn features directly from raw inputs often reduces the need for manual feature engineering. However, DNNs typically require large labelled datasets and significant computational resources, which may constrain their use in early-phase development where data availability is limited. Nonetheless, their accuracy and adaptability make them invaluable in data-rich environments such as commercial-scale manufacturing and formulation optimization.[15]

2. Convolutional Neural Networks (CNNs)

CNNs are a specialized class of DNNs optimized for image analysis tasks. By applying convolutional layers that capture spatial hierarchies and local patterns, CNNs excel at detecting visual anomalies in solid dosage forms. Applications include identification of surface defects, coating irregularities and dimensional inconsistencies in tablets and capsules.[16] CNNs are integral to automated visual inspection platforms such as QualiVision[17] and DeepInspect,[18] where they augment or replace manual inspection workflows. Training CNNs on annotated image datasets enables real-time classification of visual defects with high precision, thereby enhancing quality control speed, accuracy and reproducibility.

3. Recurrent Neural Networks (RNNs)

RNNs are designed to model sequential data and capture temporal dependencies, making them ideal for time-series analysis in pharmaceutical processes. They are employed in scenarios such as monitoring bioreactor performance, modelling degradation kinetics under various storage conditions and predicting batch outcomes based on early process indicators. A key variant, Long Short-Term Memory (LSTM) networks, addresses the limitations of traditional RNNs by preserving long-range dependencies across sequences. This capability is particularly valuable in real-time release testing (RTRT) and stability prediction, where accurate forecasting depends on understanding cumulative process history and future trajectories.[19]

Random Forests, Support Vector Machines and Graph Neural Networks in Pharmaceutical Quality Analysis

Advanced machine learning models such as Random Forests (RF), Support Vector Machines (SVMs) and Graph Neural Networks (GNNs) provide robust analytical tools for addressing complex challenges in pharmaceutical quality control and process optimization. Each model offers unique advantages depending on data type and application context.

1. Random Forests (RF)

Random Forests are ensemble models that combine multiple decision trees to enhance prediction accuracy and reduce overfitting. Their strength lies in handling both categorical and continuous variables with high robustness and interpretability. In pharmaceutical contexts, RF is used for impurity classification, batch quality prediction and variable selection in multivariate datasets. It is especially valuable in formulation and process modelling, capturing nonlinear relationships between critical material attributes (CMAs) and quality attributes (CQAs) under Quality by Design (QbD) frameworks. RF's tolerance to noise, missing values and its straightforward implementation make it practical for real-time integration in manufacturing environments.[20]

2. Support Vector Machines (SVMs)

SVMs are effective supervised models for binary classification, particularly with smaller or medium-sized datasets. By identifying the optimal hyperplane that separates data classes in high-dimensional space, SVMs deliver high precision and generalization. In pharma, they are applied to classify spectral data, detect adulterants and differentiate between compliant and non-compliant batches. SVMs are resistant to overfitting and well-suited for critical decision-making. However, they may face computational limitations with large or complex datasets, where deep learning models could offer more scalability and adaptability.[21]

3. Graph Neural Networks (GNNs)

GNNs are specialized for graph-structured data, capturing both node features and their interconnections. In pharmaceutical applications, GNNs are emerging in areas such as molecular structure analysis, reaction prediction and impurity identification. Their ability to learn from molecular graphs supports structure–activity relationship (SAR) modelling and physicochemical property prediction. Beyond molecule-level tasks, GNNs are being explored for modelling complex manufacturing workflows and dependencies between analytical parameters. While still early in adoption, GNNs present a promising frontier where traditional models struggle with relational or topological data.[22]

REGULATORY AND ETHICAL CONSIDERATIONS IN AI-DRIVEN PHARMACEUTICAL QUALITY CONTROL

The integration of Artificial Intelligence (AI) into pharmaceutical analysis and quality control offers significant potential but presents regulatory and ethical challenges. Agencies like the FDA and EMA recognize AI's role in improving product quality and efficiency but stress compliance with Good Manufacturing Practices (GMP), data integrity and risk management.[23] Initiatives such as the FDA's Emerging Technology Program (ETP) and EMA's AI Reflection Paper promote early engagement, transparency and robust validation. AI must be treated as part of the pharmaceutical control strategy, with defined roles, responsibilities and performance criteria.

Data integrity is vital, as AI performance depends on the quality of input data. Adherence to ALCOA+ principles (Attributable, Legible, Contemporaneous, Original, Accurate, etc.) is essential across data acquisition, model training and decision auditing. Poor or biased data can compromise product quality and compliance.[24] Model validation must demonstrate reproducibility, accuracy and robustness under intended use. Protocols should address overfitting, model drift and handling of unseen data, with periodic revalidation for adaptive models. Explainability is increasingly necessary, especially for black-box models like deep neural networks. Explainable AI (XAI) tools help interpret outputs, identify key variables and support regulatory acceptance. Without transparency, deviations, release decisions or audit responses become difficult to justify.[25]

Achieving responsible and compliant AI integration in GMP environments requires a careful balance between innovation and regulatory rigor. Continued collaboration among industry, regulators and technology developers will be essential to ensure ethical and effective implementation.

AI IN ANALYTICAL INSTRUMENTATION

Artificial Intelligence (AI) is transforming pharmaceutical analytical instrumentation by automating data acquisition, interpretation and real-time decision-making. Instruments such as spectrometers, chromatographs and imaging systems generate large, complex datasets that traditionally require expert manual analysis. AI-integrated platforms now automate peak identification, impurity profiling, pattern recognition and multivariate correlations, minimizing human error, reducing subjectivity and enhancing analytical speed, precision and regulatory compliance. These advances are particularly impactful in spectral analysis, chromatography and process monitoring.

Spectral Data Analysis: NMR, IR, Raman and UV-Vis Spectroscopy

Artificial Intelligence (AI) is transforming pharmaceutical analytical instrumentation by automating data acquisition, interpretation and decision-making. Instruments such as spectrometers, chromatographs and imaging systems produce vast, complex datasets that traditionally require expert analysis. AI-integrated platforms now automate tasks like peak identification, impurity profiling, pattern recognition and multivariate data correlation. This reduces human error, minimizes subjectivity and enhances analytical speed, precision and regulatory compliance, especially in spectral interpretation, chromatography and process monitoring.

Spectroscopic techniques such as Nuclear Magnetic Resonance (NMR), Infrared (IR), Raman and Ultraviolet-Visible (UV-Vis) spectroscopy play a central role in identifying active pharmaceutical ingredients (APIs), elucidating molecular structures and detecting impurities. Manual interpretation of such data is often time-consuming and error-prone, particularly with complex formulations. AI significantly improves the efficiency and accuracy of these techniques. In NMR, deep learning algorithms can deconvolute overlapping peaks, assign chemical shifts and match spectral data with large compound libraries. In IR and Raman spectroscopy, machine learning models like support vector machines (SVMs) and convolutional neural networks (CNNs) classify spectral fingerprints, identify functional groups and detect excipients or contaminants. AI also enables real-time monitoring by comparing live spectra with validated reference profiles.[26]

In UV-Vis spectroscopy, AI improves quantification of APIs within complex matrices, addressing issues such as baseline drift and peak overlap. Supervised models enhance sensitivity and specificity, while unsupervised methods like Principal Component Analysis (PCA) are used to identify trends, outliers or polymorphic transformations during stability testing. These capabilities make AI-driven spectral analysis highly valuable in high-throughput quality control (QC) labs and continuous manufacturing environments.[27]

Tools like Mnova AI from Mestrelab demonstrate how AI is integrated into routine spectral workflows. This platform automates processing and interpretation of NMR, MS and other spectra using deep learning models trained on large datasets. It performs peak picking, spectral assignment and structure elucidation, while enabling data fusion across analytical techniques to support impurity profiling and molecular characterization with minimal manual input.[28] Similarly, ChemOS by DeepMatter leverages AI to automate experimental design and data analysis. By interfacing with laboratory instruments, ChemOS applies reinforcement learning and predictive modelling to recommend optimal reaction conditions and streamline method development. Its integration into closed-loop systems supports adaptive, real-time experimentation.[29]

Together, these AI-enhanced platforms exemplify how analytical instrumentation is evolving into intelligent, automated systems. By improving speed, consistency and insight across spectral data analysis, they are redefining pharmaceutical quality control and R&D workflows.

Chromatographic Data Interpretation: HPLC, GC and LC-MS Data

Chromatographic techniques such as High-Performance Liquid Chromatography (HPLC), Gas Chromatography (GC) and Liquid Chromatography–Mass Spectrometry (LC-MS) are foundational in pharmaceutical analysis for quantifying active pharmaceutical ingredients (APIs), identifying impurities and ensuring batch consistency. These methods generate complex datasets requiring accurate peak detection, retention time alignment and compound identification. Traditionally, chromatographic data interpretation has relied on manual input and expert judgment, often resulting in variability, inefficiency and potential human error.

Artificial Intelligence (AI) is increasingly enhancing chromatographic workflows by automating analysis, improving precision and enabling real-time decision-making. In HPLC and GC, AI models detect retention time shifts, resolve overlapping peaks and identify co-eluting compounds that conventional algorithms may miss. Machine learning, trained on historical batch data, can flag subtle anomalies, such as degradation trends or system drift, providing early warnings of quality deviations or equipment malfunctions.

In LC-MS, where the integration of chromatographic separation with mass spectral analysis introduces additional complexity, AI plays a critical role in spectral deconvolution and compound elucidation. Deep learning models match MS/MS fragmentation patterns to molecular structures with high accuracy, even in complex or novel formulations. These capabilities support applications like stability studies, impurity profiling and real-time detection of out-of-specification (OOS) results, which are vital for continuous manufacturing and Real-Time Release Testing (RTRT).

Tools such as Empower™ 3, ChromGenius AI™ and MolDiscovery exemplify this AI-driven transformation. Empower 3, a widely adopted chromatography data system by Waters Corporation, integrates AI-based modules to enhance peak integration, reduce manual processing and support PAT-based real-time analytics for faster product release.[30] ChromGenius AI™ by ACD/Labs leverages chemoinformatics and predictive modelling to streamline method development, forecasting retention times and suggesting optimal chromatographic conditions, particularly for new chemical entities or unknown impurities.[31] MolDiscovery, tailored for LC-MS workflows, employs deep learning to interpret MS/MS spectra and identify small molecules by comparing experimental data with large-scale spectral databases.[32] Its learning-based approach outperforms traditional rule-based systems, offering higher accuracy in metabolite and degradation product identification under high-throughput QC demands.

Collectively, these AI-enabled tools enhance consistency, scalability and interpretability in chromatographic data analysis, aligning with regulatory expectations and accelerating pharmaceutical development and quality control.

Mass Spectrometry and Structural Elucidation

Mass spectrometry (MS) is a central technique in pharmaceutical analysis, essential for molecular identification, structural elucidation and impurity characterization. However, interpreting tandem MS (MS/MS) data remains complex due to signal overlap, background noise and diverse fragmentation patterns, particularly in mixed samples or novel compounds. Traditional rule-based approaches often fall short in untargeted analysis, requiring extensive manual interpretation and iterative database matching.

Artificial Intelligence (AI) overcomes these limitations through advanced pattern recognition and data-driven modelling. Deep learning algorithms, trained on vast spectral libraries, can accurately predict fragmentation pathways and structural features. Graph Neural Networks (GNNs), in particular, simulate fragmentation behaviour by modelling molecules as graph structures that reflect atomic connectivity and chemical properties under specific ionization conditions. These AI models not only

match experimental MS/MS spectra with candidate structures from large-scale databases but can also suggest novel structures and prioritize likely molecular identities. Such capabilities are especially valuable in early drug discovery, metabolite profiling and complex degradant identification.

In parallel, AI is revolutionizing impurity profiling, an essential element of pharmaceutical quality control. Conventional impurity analysis via MS often depends on expert judgment and labour-intensive workflows. AI enables automated detection, classification and tracking of impurities across the development and manufacturing lifecycle. Supervised learning models, trained on historical data, can detect trace-level peaks, distinguish known from unknown species and infer their likely origin, whether as synthetic byproducts, degradation products or excipient interactions. Platforms like MolDiscovery utilize deep learning to score and rank impurity candidates based on spectral similarity, isotope distribution, fragmentation patterns and retention behaviour, even in the absence of complete reference data.

Some systems further employ Bayesian inference or probabilistic modelling to assign confidence levels to predictions and estimate structural features in low-data scenarios. AI also aids in predicting retention times and retrosynthetic pathways, contributing to comprehensive impurity profiling when combined with chromatographic and spectroscopic data. These integrated systems allow monitoring of impurity trends across batches, detection of deviations and early warning of potential out-of-specification (OOS) results, supporting real-time release testing (RTRT) and Quality by Design (QbD) strategies.[33]

By automating MS data interpretation and impurity profiling, AI enhances analytical accuracy, increases throughput, reduces human error and accelerates decision-making in both research and quality control settings. This shift toward intelligent, predictive analysis aligns closely with evolving regulatory expectations and the push for more robust pharmaceutical quality assurance.

AI IN QUALITY CONTROL APPLICATIONS

Artificial Intelligence (AI) is transforming pharmaceutical quality control (QC) by enabling predictive, real-time and automated assessments. Traditional QC methods, largely manual and retrospective, are limited by subjectivity, delayed detection and inconsistent outcomes. AI overcomes these challenges by automating anomaly detection, enhancing data interpretation and supporting early deviation alerts.

AI models are now integrated across key QC domains, including visual inspection, stability prediction, impurity tracking and batch release. These tools align with regulatory frameworks such as Quality by Design (QbD), Process Analytical Technology (PAT) and Real-Time Release Testing (RTRT), promoting proactive quality assurance and continuous process improvement.[34,35]

By minimizing human error, increasing inspection throughput and ensuring data integrity, AI enhances compliance, efficiency and product consistency. Its adoption marks a shift toward smarter, more resilient QC systems that meet the demands of modern pharmaceutical manufacturing.

Visual Inspection and Defect Detection

Visual inspection plays a vital role in identifying physical defects in solid dosage forms such as tablets and capsules. Traditional manual inspection methods, though widely used, are subject to inconsistency, operator fatigue and subjective judgment. Artificial Intelligence (AI), particularly through Convolutional Neural Networks (CNNs), has transformed this process by enabling automated, real-time and highly accurate defect detection.[36]

CNNs trained on large annotated image datasets can classify and detect a wide range of defects, including surface cracks, coating anomalies, embossing errors, shape deformities and colour inconsistencies. Unlike conventional rule-based systems, AI models adapt to variability in lighting orientation and geometry, resulting in more reliable inspection outcomes. These systems support 100% inline inspection, reduce false positives and generate digital records essential for GMP-compliant batch reporting and regulatory traceability.[37]

Platforms like DeepInspect and QualiVision exemplify the application of AI in visual quality control. DeepInspect utilizes high-speed cameras and adaptive CNN algorithms to identify microcracks, coating defects and misprints in real time, with integrated alert mechanisms and reject handling systems for immediate quality interventions. Its continuous learning capabilities allow ongoing refinement based on live production data.[38] QualiVision offers modular inspection units compatible with tablets, capsules and blister packs, using multi-angle imaging and machine learning to detect edge defects, coating bubbles and foreign particles. Its compatibility with Manufacturing Execution Systems (MES) and Laboratory Information Management Systems (LIMS) ensures traceable, audit-ready integration across diverse product lines.[39]

By automating visual inspection, AI enhances detection accuracy, speeds up quality control processes and reduces human variability, ultimately contributing to safer, more consistent pharmaceutical products and streamlined regulatory compliance.

Predictive Stability and Shelf-Life Modelling

Traditional pharmaceutical stability testing, guided by ICH protocols, often spans up to 24 months and demands significant time and resources. Artificial Intelligence

(AI) is redefining this paradigm by enabling predictive modelling approaches that forecast product degradation and shelf life based on historical data, formulation parameters and environmental conditions. These data-driven methods accelerate development decisions and reduce dependence on long-term empirical testing.

Machine learning models, such as random forests, regression algorithms and neural networks, can be trained on historical stability datasets to reveal correlations between formulation attributes (e.g., pH, excipient composition, moisture content) and degradation kinetics. These models allow real-time predictions of shelf life and stability-limiting factors, offering actionable insights during formulation development, scale-up and post-approval changes. Integration with real-time sensor inputs, such as temperature, humidity and assay values, further refines predictive accuracy, particularly during technology transfer and real-time release testing (RTRT). This approach aligns with Quality by Design (QbD) and Process Analytical Technology (PAT) principles, enhancing regulatory responsiveness and proactive quality control.

Platforms such as Stability. AI and ValGenesis iRisk™ exemplify the practical deployment of AI in stability forecasting. Stability. AI applies machine learning to simulate degradation trends, predict shelf life and assess packaging configurations. It supports "what-if" scenario modelling, risk-based decision-making and generates traceable, regulatory-aligned reports through cloud-based dashboards.[40] ValGenesis iRisk™ integrates AI with Bayesian inference to construct stability risk profiles using formulation, batch and manufacturing data. It prioritizes experiments based on model uncertainty, generates interactive decision trees and allows lifecycle-based model refinement. Its integration with LIMS and digital QMS platforms supports ICH Q8–Q10 compliance and fosters cross-functional collaboration.[41]

Together, these AI-enabled tools are shifting stability assessment from static, time-bound testing to dynamic, predictive modelling, improving speed-to-market, optimizing product quality and enhancing regulatory agility in modern pharmaceutical development.

AI for Raw Material and Process Validation

Artificial Intelligence (AI) is enhancing the scope and precision of Process Analytical Technology (PAT) by enabling real-time, intelligent monitoring of critical process parameters (CPPs) and critical quality attributes (CQAs) during pharmaceutical manufacturing. Traditional PAT systems, typically reliant on chemometric models and spectroscopic sensors such as NIR, Raman and FTIR, are limited by predefined algorithms and fixed process assumptions. AI, however, introduces adaptive learning and dynamic data interpretation to elevate process validation and control.

Machine learning models, including multivariate regression, neural networks and reinforcement learning, analyse complex, high-frequency process data to detect anomalies, predict trends and proactively adjust control strategies. These models can identify early deviations in parameters like blend uniformity, moisture content or material flow, issues that conventional systems may overlook. AI also supports predictive maintenance by flagging instrumentation drift or process instability before failure occurs, reducing downtime and ensuring batch consistency.

The integration of AI enables the creation of digital twins, virtual simulations of physical manufacturing processes, that facilitate real-time scenario modelling and continuous optimization. These intelligent systems strengthen process robustness, support continuous manufacturing and align closely with Quality by Design (QbD) principles. Moreover, AI-augmented PAT aligns with regulatory frameworks such as the FDA's PAT Guidance, offering improved process transparency, compliance and traceability.[42] Ultimately, AI-driven process validation fosters a shift from reactive quality assurance to predictive, data-informed control across the pharmaceutical manufacturing lifecycle.

Real-Time Release Testing (RTRT)

Real-Time Release Testing (RTRT) enables immediate product release based on in-process data, eliminating reliance on end-product testing. AI enhances RTRT by enabling continuous evaluation of CPPs and CQAs through machine learning models that correlate real-time sensor data with product quality outcomes.

Deep learning algorithms predict final batch quality based on in-line or at-line data from blending, granulation or compression steps. This facilitates automated, high-confidence batch release decisions, reduces release cycle times and improves regulatory compliance. AI also dynamically adjusts control thresholds by accounting for process variability, supporting robust, adaptive quality control.

When integrated with Manufacturing Execution Systems (MES) and electronic batch records (EBR), AI enables traceable, audit-ready and fully digital RTRT workflows. This represents a paradigm shift, transforming pharmaceutical QC from reactive testing to real-time, data-driven quality assurance.[43]

CASE STUDIES AND INDUSTRY APPLICATIONS

Aizon Platform for Biopharma QC

Aizon is a cloud-based, AI-powered platform designed specifically for the pharmaceutical and biopharmaceutical industries. It integrates advanced machine learning, data contextualization and predictive analytics into manufacturing and quality control (QC) environments. One of Aizon's key strengths is its ability to unify disparate data sources, such as PAT instruments, MES, LIMS and IoT devices, into a single analytics

platform that supports real-time monitoring and decision-making. In biopharmaceutical QC, Aizon's AI models help identify sources of process variability, predict deviations and optimize batch yields.[44]

For example, in a cell culture-based production process, Aizon can track hundreds of variables simultaneously, such as temperature, dissolved oxygen, pH and nutrient levels, using AI to forecast batch performance and flag anomalies before they result in failures. The platform also supports predictive maintenance for equipment and enables automated generation of audit trails, aligning with data integrity and FDA's 21 CFR Part 11 compliance. By embedding AI into GMP workflows, Aizon not only improves batch consistency and reduces the need for retrospective investigations but also helps organizations move toward a fully digital, QbD-based approach to biopharma manufacturing.

Seeq + AWS ML for Manufacturing Data Monitoring

The collaboration between Seeq, an advanced analytics platform and Amazon Web Services (AWS) Machine Learning brings scalable AI capabilities to pharmaceutical and biotech manufacturers focused on process optimization and real-time monitoring. Seeq enables users to visualize and contextualize large volumes of time-series data from sensors, control systems and production databases. By integrating AWS's machine learning services, such as SageMaker, users can apply predictive models without needing deep coding expertise.[45]

In pharmaceutical environments, this partnership supports predictive quality assurance by enabling anomaly detection, root cause analysis and yield forecasting across manufacturing lines. For instance, manufacturers can use AI to monitor a fermentation process in real time, detect early indicators of batch deviation and receive recommendations for corrective actions, long before product quality is compromised. The platform also allows users to create "data capsules" for digital documentation, enhancing traceability and regulatory audit readiness. Seeq's visual tools paired with AWS's computing power make AI more accessible to process engineers, facilitating faster insights and better decision-making. This combination empowers manufacturers to transition from reactive troubleshooting to proactive quality control, aligning with PAT and continuous improvement frameworks.

AstraZeneca's DPK Model for Predictive Dissolution

AstraZeneca's Drug Product Knowledge (DPK) model represents a pioneering use of AI in predictive pharmaceutical analysis. The DPK platform integrates machine learning algorithms with formulation and process data to simulate and predict in vitro dissolution behaviour of solid oral dosage forms. Traditionally, dissolution testing is a time-consuming analytical procedure required for bioequivalence studies, formulation optimization and batch release. The DPK model addresses this bottleneck by using AI to forecast dissolution profiles under various formulation compositions and manufacturing conditions.[46]

Built on historical data and mechanistic modelling, the DPK system allows formulators to simulate how changes in excipients, compression force or granule size distribution will impact dissolution outcomes, without needing to conduct physical experiments for every iteration. This accelerates development timelines, enhances design space understanding and supports QbD implementation. Furthermore, the model is continuously updated with real-world production data, improving its predictive accuracy and enabling its use in real-time quality assurance. The DPK model is an example of how AI can be embedded into the core of pharmaceutical R&D, turning traditional, resource-heavy lab methods into streamlined, data-driven simulations.

Atomwise's AI for Drug Structure–Activity Relationships (SAR)

Atomwise leverages deep learning and structure-based drug design to revolutionize early-stage drug discovery. Its AI platform uses convolutional neural networks to analyse 3D representations of protein-ligand interactions, predicting the structure–activity relationship (SAR) of candidate compounds. This allows researchers to rapidly screen billions of molecules in silico and identify those most likely to bind with a biological target of interest.[47]

In pharmaceutical development, SAR modelling is fundamental to optimizing potency, selectivity and pharmacokinetics. Traditionally, SAR studies involve iterative cycles of synthesis and testing, often taking months to refine a lead compound. Atomwise's AI accelerates this by simulating molecular docking and predicting binding affinities with high accuracy, even for novel targets lacking extensive biological data. The platform has been used in collaborations with large pharmaceutical firms and academic institutions to identify lead candidates for cancer, infectious diseases and neurological conditions. Importantly, Atomwise's predictions are interpretable, enabling medicinal chemists to rationalize AI-generated suggestions and guide synthesis strategies. This represents a shift from empirical SAR methods toward intelligent, model-guided drug design, reducing cost, time and failure rates in early development.

INTEGRATION WITH QUALITY BY DESIGN (QBD) AND PAT

Role of AI in QbD Framework: Design Space Exploration and Control Strategies

Quality by Design (QbD) is a systematic, science-based approach to pharmaceutical development that emphasizes understanding and controlling formulation and manufacturing variables to ensure product quality. A cornerstone of QbD is the identification of a "design space", a multidimensional region within which changes to input variables do not negatively impact critical

quality attributes (CQAs). Traditionally, this space is defined through labour-intensive Design of Experiments (DoE) and statistical modelling. AI transforms QbD by enabling faster and deeper exploration of complex design spaces using machine learning, deep learning and optimization algorithms.

AI models trained on historical development and manufacturing data can identify non-linear relationships between process parameters and product outcomes that traditional methods may miss. These models support rapid simulations, sensitivity analysis and optimization scenarios, allowing development teams to explore a wider range of formulation compositions and processing conditions with minimal lab experimentation. Additionally, reinforcement learning algorithms can suggest optimal process settings and predict how deviations might impact product quality. This leads to more robust control strategies and proactive risk management throughout the product lifecycle.[48]

Furthermore, AI facilitates adaptive QbD, where models are continuously refined using new data from commercial-scale batches, process changes or market feedback. This dynamic approach enhances lifecycle management and supports continual improvement initiatives. Regulatory bodies such as the FDA and EMA increasingly recognize the value of AI-driven design space exploration, provided the models are validated and interpretable. As a result, AI enables a more efficient, data-rich and compliant implementation of QbD principles in both R&D and manufacturing environments.

Enhancing PAT Through Machine Learning Models

Process Analytical Technology (PAT) aims to design, analyse and control pharmaceutical manufacturing processes through timely measurements of critical quality and process parameters. While traditional PAT relies on chemometric models and fixed control rules, the integration of machine learning significantly enhances its capabilities. AI enables dynamic, real-time decision-making by learning from vast historical and real-time data to predict process behaviour, detect anomalies and suggest optimal control actions.

Machine learning models, such as random forests, support vector machines (SVMs) and neural networks, can be trained on multivariate sensor data (e.g., temperature, humidity, blend uniformity) collected during manufacturing. These models help identify subtle trends and complex interactions among variables that may not be apparent using conventional statistical tools. For example, AI can predict endpoint determination in blending or drying operations with greater precision, improving throughput and minimizing energy consumption. In continuous manufacturing, AI models also facilitate the development of soft sensors, virtual measurements derived from real-time data, that offer insights when physical sensors are impractical or invasive.[49]

By integrating AI into PAT, pharmaceutical companies can implement more advanced feedback and feedforward control strategies, reduce process variability and improve batch consistency. These systems also enable early fault detection, predictive maintenance and root-cause analysis, minimizing downtime and improving operational efficiency. Moreover, AI-driven PAT aligns with Real-Time Release Testing (RTRT) objectives by providing a high level of assurance in product quality based on process understanding and control. In this way, AI transforms PAT from a monitoring tool into a predictive and prescriptive engine that supports agile, efficient and high-quality pharmaceutical manufacturing.

Ensuring Compliance and Traceability

As AI becomes increasingly embedded in pharmaceutical development and manufacturing, ensuring regulatory compliance and data traceability is critical for successful adoption. Regulatory bodies like the FDA, EMA and ICH emphasize the need for transparent, validated and auditable systems, especially when AI is used to make decisions impacting product quality. This includes adherence to Good Automated Manufacturing Practice (GAMP), 21 CFR Part 11 and data integrity standards under ALCOA+ principles (Attributable, Legible, Contemporaneous, Original, Accurate and more).[50]

AI-driven systems must be designed to maintain a clear chain of data custody, from input (sensor data, raw materials, analytical readings) to output (model decisions, batch release justification). This requires detailed documentation of model architecture, training datasets, version control and performance metrics. Importantly, machine learning models, especially those used in predictive quality assurance or real-time release, must be validated using statistically sound approaches, including cross-validation, blind testing and robustness analysis. Regulators expect that any updates to the model (e.g., in adaptive learning scenarios) are accompanied by change controls and revalidation.

Explainability is another key requirement. Models must be interpretable or paired with explainable AI (XAI) techniques to justify their decisions, especially in critical applications like OOS investigation, impurity classification or batch release. Platforms that integrate AI with electronic batch records (EBRs), LIMS and MES further enhance traceability by maintaining secure, time-stamped records that support inspections and audits.[51,52] Ultimately, by incorporating transparency, validation and traceability into their AI strategies, pharmaceutical companies can gain regulatory confidence and maximize the benefits of digital transformation in quality systems.

CHALLENGES AND LIMITATIONS

Data Quality and Availability

AI's performance is highly dependent on the availability of clean, well-annotated and comprehensive datasets. In pharmaceutical settings, historical data are often fragmented, inconsistent or unstructured due to variations in instrumentation, manual entry errors or lack of standardization across sites. Proprietary restrictions further limit data sharing and model generalizability. Without large, contextualized datasets, AI models may deliver inaccurate or non-reproducible results, particularly in applications such as stability prediction or impurity profiling. Addressing this requires improved digital infrastructure, standardized data formats and cross-functional collaboration to ensure data readiness for AI-driven systems.

Model Validation and Regulatory Acceptance

AI adoption is hindered by the complexity of validating data-driven models under current regulatory frameworks. Agencies such as the FDA and EMA require transparent justification for tools affecting product quality or compliance. Unlike deterministic systems, AI models, especially those using adaptive learning, pose challenges in terms of validation, change control and lifecycle management. The absence of standardized guidelines for AI model validation adds further uncertainty. To bridge this gap, industry and regulators must co-develop risk-based validation frameworks with defined performance metrics and revalidation protocols to support trustworthy AI deployment.

Black-Box Algorithms and Interpretability

Many high-performing AI models, such as deep neural networks, lack interpretability, raising concerns in a regulated environment where traceability and justification are critical. Quality professionals must understand model reasoning, especially when AI influences batch release or flags anomalies. The growing field of Explainable AI (XAI) offers tools to improve transparency, yet a trade-off often remains between model accuracy and explainability. Mitigating this limitation involves selecting interpretable models when possible, integrating domain expertise and maintaining thorough documentation of model logic and inputs.[53]

Integration with Legacy Systems

Pharmaceutical operations commonly depend on legacy platforms (e.g., LIMS, MES) that are not designed for AI integration, leading to data silos and interoperability issues. Implementing AI in such environments involves navigating technical incompatibilities, increased validation burden and high upgrade costs. Additionally, retrofitting AI into GMP-compliant systems requires extensive documentation and risk controls. A phased integration strategy, starting with modular AI solutions and investing in cloud infrastructure or middleware, is critical for bridging legacy gaps. Successful transformation also depends on fostering digital readiness across quality, IT and manufacturing teams.

FUTURE DIRECTIONS AND RESEARCH GAPS

Explainable AI (XAI)

As AI systems become more embedded in pharmaceutical quality control, interpretability becomes critical. Explainable AI (XAI) addresses the "black-box" issue of complex models by providing human-understandable outputs, such as feature importance scores, decision pathways and visualizations. In regulated domains like batch release or impurity classification, XAI enhances transparency, supports regulatory acceptance and facilitates internal decision-making. Ongoing research focuses on domain-specific XAI methods that balance interpretability with predictive performance. As regulatory bodies increasingly require justification for algorithmic decisions, XAI will become central to trustworthy AI implementation in pharma.

Federated Learning for Collaborative Model Development

Data sharing restrictions remain a major obstacle to developing robust pharmaceutical AI models. Federated learning offers a privacy-preserving alternative by allowing decentralized training across multiple organizations without exposing proprietary data. Only model parameters are shared, enabling collaborative development of high-quality models for rare conditions, stability forecasting or anomaly detection. Research is advancing in secure model aggregation, communication efficiency and federated governance protocols. Broad adoption of this paradigm could facilitate cross-industry innovation while maintaining data confidentiality and IP protection.

AI in Personalized Medicine and Adaptive QC

AI is essential to managing the growing complexity of personalized therapeutics, such as gene therapies and individualized biologics. These modalities require flexible, real-time quality control strategies that adapt to patient-specific inputs and batch-to-batch variability. AI can optimize process parameters on a per-batch basis and enable dynamic specification limits based on cumulative process data. This shift from static QC frameworks to adaptive systems will demand new approaches to process validation, risk assessment and regulatory oversight. Research is needed to ensure AI tools used in this context are reliable, compliant and capable of managing high variability.

Regulatory Sandboxes and Standards Development

Wider AI adoption in pharma hinges on harmonized regulatory frameworks. Regulatory sandboxes, controlled environments that allow safe testing of AI applications under agency oversight, are emerging globally to bridge the innovation-compliance gap. These initiatives enable real-world validation of AI systems while informing future policy. Concurrently, international standardization efforts (e.g., ICH, ISO, ISPE) are shaping guidelines for AI lifecycle management, validation and ethical use. Continued collaboration between regulators, industry and academia

is vital to align innovation with compliance and to foster responsible AI integration across the pharmaceutical value chain.

CONCLUSION

The integration of Artificial Intelligence into pharmaceutical drug analysis and quality control represents a transformative advancement in the industry's journey toward smarter, faster and more reliable quality systems. This review has explored the core applications of AI across the pharmaceutical analytical spectrum, from spectral data interpretation and chromatographic profiling to impurity detection, predictive stability modelling and real-time process control. Key platforms such as Aizon, Stability. AI, DeepInspect and ValGenesis iRisk™ illustrate how AI-driven tools are reshaping the way quality is monitored, assessed and assured.

AI holds the potential to revolutionize drug quality control by enabling real-time decision-making, reducing manual errors, optimizing process parameters and forecasting quality issues before they arise. These advancements support not only higher product quality and safety but also faster time-to-market and enhanced regulatory compliance. AI models can capture complex, multivariate patterns across data-rich environments, making them ideal for continuous manufacturing, personalized medicine and adaptive quality systems.

However, realizing this potential requires strategic implementation. Pharmaceutical companies must invest in robust data infrastructure, validated and explainable AI models and cross-functional teams skilled in both domain knowledge and data science. Compliance with evolving regulatory expectations and the adoption of digital quality management systems will be essential. Collaborative efforts, including federated learning and regulatory sandboxes, will play a crucial role in overcoming current limitations and standardizing best practices. Ultimately, AI is not merely a tool, it is a strategic enabler of a more agile, intelligent and quality-driven pharmaceutical future.

REFERENCES

1. Alanazi MMS, Alruwaili YSJ, Alruwaili MMR, Alrwayli HMR, Alruwaili MJN, Alanazi FHBF, et al. Advancements in Analytical Techniques for Pharmaceutical Quality Control. Journal of International Crisis and Risk Communication Research, 2024; 7(S10): 51.
2. Saha GC, Eni LN, Saha H, Parida PK, Rathinavelu R, Jain SK, et al. Artificial intelligence in pharmaceutical Manufacturing: Enhancing quality control and decision making. Rivista Italiana di Filosofia Analitica Junior, 2023; 14(2): 2023.
3. de Matas M, De Beer T, Folestad S, Ketolainen J, Lindén H, Lopes JA, et al. Strategic framework for education and training in Quality by Design (QbD) and process analytical technology (PAT). European Journal of Pharmaceutical Sciences, 2016; 90: 2–7.
4. Panzitta M, Calamassi N, Sabatini C, Grassi M, Spagnoli C, Vizzini V, et al. Spectrophotometry and pharmaceutical PAT/RTRT: Practical challenges and regulatory landscape from development to product lifecycle. Int J Pharm., 2021; 601: 120551.
5. Saini JPS, Thakur A, Yadav D. AI driven Innovations in Pharmaceuticals: Optimizing Drug Discovery and Industry Operations. RSC Pharmaceutics, 2025.
6. Suriyaamporn P, Pamornpathomkul B, Patrojanasophon P, Ngawhirunpat T, Rojanarata T, Opanasopit P. The artificial intelligence-powered new era in pharmaceutical research and development: A review. AAPS PharmSciTech., 2024; 25(6): 188.
7. Lehr J, Philipps J, Hoang VN, Von Wrangel D, Krüger J. Supervised learning vs. unsupervised learning: A comparison for optical inspection applications in quality control. In: Iop conference series: Materials science and engineering. IOP Publishing, 2021; 012049.
8. Islam MR, Zamil MZH, Rayed ME, Kabir MM, Mridha MF, Nishimura S, et al. Deep learning and computer vision techniques for enhanced quality control in manufacturing processes. IEEE Access, 2024; 12: 121449 – 121479.
9. Ghazwani M, Hani U. Data driven analysis of tablet design via machine learning for evaluation of impact of formulations properties on the disintegration time. Ain Shams Engineering Journal, 2025; 16(9): 103512.
10. Kalusivalingam AK, Sharma A, Patel N, Singh V. Leveraging Random Forests and Gradient Boosting for Enhanced Predictive Analytics in Operational Efficiency. International Journal of AI and ML., 2022; 3(9).
11. Igne B, Drennen III JK, Anderson CA. Improving near-infrared prediction model robustness with support vector machine regression: a pharmaceutical tablet assay example. Appl Spectrosc, 2014; 68(12): 1348–56.
12. Allen B. The role of the FDA in ensuring the safety and efficacy of artificial intelligence software and devices. Journal of the American College of Radiology, 2019; 16(2): 208–10.
13. Martinez JC, Guzmán-Sepúlveda JR, Bolañoz Evia GR, Córdova T, Guzmán-Cabrera R. Enhanced quality control in pharmaceutical applications by combining raman spectroscopy and machine learning techniques. Int J Thermophys, 2018; 39(6): 79.
14. Martinez JC, Guzmán-Sepúlveda JR, Bolañoz Evia GR, Córdova T, Guzmán-Cabrera R. Enhanced quality control in pharmaceutical applications by combining raman spectroscopy and machine learning techniques. Int J Thermophys, 2018; 39(6): 79.

15. Teja TB, Sekar M, Pallavi T, Mettu S, Murthy TE, Mat Rani NNI, et al. Role of Artificial Neural Networks in Pharmaceutical Sciences. Journal of Young Pharmacists, 2022; 14(1): 6–14.
16. Saha GC, Eni LN, Saha H, Parida PK, Rathinavelu R, Jain SK, et al. Artificial intelligence in pharmaceutical Manufacturing: Enhancing quality control and decision making. Rivista Italiana di Filosofia Analitica Junior, 2023; 14(2): 116–26.
17. Quality Assurance in Pharma Industry: Solutions For Print [Internet]. [cited 2025 June 7];Available from: https://www.qualivision.ch/industries_we_serve/pharma/
18. Zhou Q, Chen R, Huang B, Xu W, Yu J. DeepInspection: Deep learning based hierarchical network for specular surface inspection. Measurement, 2020; 160: 107834.
19. Wong WC, Chee E, Li J, Wang X. Recurrent neural network-based model predictive control for continuous pharmaceutical manufacturing. Mathematics, 2018; 6(11): 242.
20. Zhang H, Zhao M, Liu L, Zhong H, Liang Z, Yang Y, et al. Deep multimodel cascade method based on CNN and random forest for pharmaceutical particle detection. IEEE Trans Instrum Meas, 2020; 69(9): 7028–42.
21. Igne B, Drennen III JK, Anderson CA. Improving near-infrared prediction model robustness with support vector machine regression: a pharmaceutical tablet assay example. Appl Spectrosc, 2014; 68(12): 1348–56.
22. Shang X, Zhang M, Sun D, Liang Y, Badrick T, Hu Y, et al. Enhanced patient-based real-time quality control using the graph-based anomaly detection. Clinical Chemistry and Laboratory Medicine (CCLM), 2024; 62(12): 2451–60.
23. Kabir M, Rana MRH, Debnath A. The Role of Quality Assurance in Accelerating Pharmaceutical Research and Development: Strategies for Ensuring Regulatory Compliance and Product Integrity. Integrative Biomedical Research, 2024; 8(12): 1–11.
24. Durá M, Sánchez-García A, Sáez C, Leal F, Chis AE, González-Vélez H, et al. Towards a computational approach for the assessment of compliance of ALCOA+ Principles in pharma industry. In: Challenges of Trustable AI and Added-Value on Health. IOS Press, 2022; 755–9.
25. Polzer A, Fleiß J, Ebner T, Kainz P, Koeth C, Thalmann S. Validation of AI-based information systems for sensitive use cases: Using an XAI approach in pharmaceutical engineering. In: HICSS, 2022; 1–10.
26. Awotunde O, Roseboom N, Cai J, Hayes K, Rajane R, Chen R, et al. Discrimination of substandard and falsified formulations from genuine pharmaceuticals using NIR spectra and machine learning. Anal Chem., 2022; 94(37): 12586–94.
27. Ioele G, De Luca M, Dinç E, Oliverio F, Ragno G. Artificial neural network combined with principal component analysis for resolution of complex pharmaceutical formulations. Chem Pharm Bull (Tokyo), 2011; 59(1): 35–40.
28. Mäkelä A V, Heikkilä O, Kilpeläinen I, Heikkinen S. ImatraNMR: Novel software for batch integration and analysis of quantitative NMR spectra. Journal of Magnetic Resonance, 2011; 211(2): 186–94.
29. Sim M, Vakili MG, Strieth-Kalthoff F, Hao H, Hickman RJ, Miret S, et al. ChemOS 2.0: An orchestration architecture for chemical self-driving laboratories. Matter., 2024; 7(9): 2959–77.
30. Maziarz M, Rainville P, Naughton S. Continued Performance Verification of Analytical Procedures Using Control Charts of Empower Chromatography Data Software. Milford: London, UK., 2019; 1–7.
31. Dossin E, Martin E, Diana P, Castellon A, Monge A, Pospisil P, et al. Prediction models of retention indices for increased confidence in structural elucidation during complex matrix analysis: application to gas chromatography coupled with high-resolution mass spectrometry. Anal Chem., 2016; 88(15): 7539–47.
32. Cao L, Guler M, Tagirdzhanov A, Lee YY, Gurevich A, Mohimani H. MolDiscovery: learning mass spectrometry fragmentation of small molecules. Nat Commun, 2021; 12(1): 3718.
33. Kakhi M, Li J, Dorantes A. Regulatory experience with continuous manufacturing and real time release testing for dissolution in new drug applications. J Pharm Sci., 2023; 112(10): 2604–14.
34. Jiang M, Severson KA, Love JC, Madden H, Swann P, Zang L, et al. Opportunities and challenges of real-time release testing in biopharmaceutical manufacturing. Biotechnol Bioeng, 2017; 114(11): 2445–56.
35. Ettalibi A, Elouadi A, Mansour A. AI and computer vision-based real-time quality control: a review of industrial applications. Procedia Comput Sci., 2024; 231: 212–20.
36. Jha SB, Babiceanu RF. Deep CNN-based visual defect detection: Survey of current literature. Comput Ind., 2023; 148: 103911.
37. Pathak KA, Kafle P, Vikram A. Deep learning-based defect detection in film-coated tablets using a convolutional neural network. Int J Pharm., 2025; 671: 125220.
38. Gelatin Capsule Inspection Using DeepInspect [Internet]. [cited 2025 June 7];Available from: https://switchon.io/gelatin-capsule-inspection-using-deepinspect/
39. QualiVision - A leader in machine vision quality control [Internet]. [cited 2025 June 7];Available from: https://www.qualivision.ch/
40. Stability AI [Internet]. [cited 2025 June 7];Available from: https://stability.ai/
41. AI-Powered Digitalization for Life Sciences | ValGenesis [Internet]. [cited 2025 June 7];Available from: https://www.valgenesis.com/
42. Mirakhori F, Niazi SK. Harnessing the AI/ML in drug and biological products discovery and

development: the regulatory perspective. Pharmaceuticals, 2025; 18(1): 47.
43. Bosshard P, Schneider M, Fretz R. Case Study 7: Manufacturing Execution Systems and Electronic Batch Records. In: Pharmaceutical Computer Systems Validation. CRC Press, 2016; 531–46.
44. Aizon – Intelligent GxP Manufacturing [Internet]. [cited 2025 June 7];Available from: https://www.aizon.ai/
45. Seeq Achieves AWS Manufacturing and Industrial Competency [Internet]. [cited 2025 June 7]; Available from: https://www.seeq.com/resources/press-releases/seeq-achieves-aws-manufacturing-and-industrial-competency/
46. Davies M, Jones RDO, Grime K, Jansson-Löfmark R, Fretland AJ, Winiwarter S, et al. Improving the accuracy of predicted human pharmacokinetics: lessons learned from the AstraZeneca drug pipeline over two decades. Trends Pharmacol Sci., 2020; 41(6): 390–408.
47. Nizhenkovska I, Reva T, Kuznetsova O, Nizhenkovskyi O, Chkhalo O. A comparison study of artificial intelligense-driven no-code appications for drug discovery and development, 2024; 6(52): 80–9.
48. Liu Y, Yang M, Guo Z. Reinforcement learning based optimal decision making towards product lifecycle sustainability. Int J Comput Integr Manuf, 2022; 35(10–11): 1269–96.
49. Segreto T, Teti R. Data quality evaluation for smart multi-sensor process monitoring using data fusion and machine learning algorithms. Production Engineering, 2023; 17(2): 197–210.
50. Sabale MM, Pande VA, Tagalpallewar AA, Swami AG, Pawar AT, Baheti AM. Maintaining data safety and accuracy through data integrity (DI): A comprehensive review. Res J Pharm Technol, 2024; 17(5): 2431–40.
51. Famili P, Cleary S. Laboratory Information Management System (LIMS) and Electronic Data. Analytical Testing for the Pharmaceutical GMP Laboratory, 2022; 345–73.
52. Parapalli SL. GMP Compliance and MES: Strategies for Automated Compliance Assurance. International journal of data science and machine learning, 2025; 5(01): 170–81.
53. Thalpage N. Unlocking the black box: Explainable artificial intelligence (XAI) for trust and transparency in ai systems. J Digit Art Humanit, 2023; 4(1): 31–6.